PREPAREDNESS TODAY, SAFER TOMORROW.

Mapping the Impact of the Opioid Crisis

The opioid overdose epidemic is the deadliest drug epidemic in Canadian history. In 2023, over 8,000 people in Canada lost their lives to opioid overdose, an average of 22 lives lost per day. Explore the impact of the crisis through personal stories from some of those who have been effected.

LEARN MORE

The New Way Forward

Who we protect will not change, but how we protect them will. Emergent is leading the new way forward for public health.

Learn more

Capabilities

We are a leading public health company that delivers protective and life-saving solutions to communities around the world.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    We specialize in developing, manufacturing, and supplying medical countermeasures for national security and public health preparedness.

  • Strategic Partnerships

    We leverage our specialized in-house capabilities to support biopharma innovators, governments and non-government organizations with their development and manufacturing needs. ​

At Emergent, our mission is to protect and save lives.

View our 2024 Annual Report

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness

WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure.
Read More

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027.
Read More

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand.
Read More
READ ALL NEWS